| 引用本文: |
邓佳,宋香清.2种中药注射剂治疗小儿急性上呼吸道感染的成本-效果比及社会效益评价[J].湖南中医药大学学报,2017,37(7):762-766[点击复制] |
|
| |
|
|
| 本文已被：浏览 1859次 下载 498次 |
| 2种中药注射剂治疗小儿急性上呼吸道感染的成本-效果比及社会效益评价 |
| 邓佳,宋香清 |
| (湖南省妇幼保健院药学部, 湖南 长沙 410008;湖南省肿瘤医院药学部, 湖南 长沙 410013) |
| 摘要: |
| 目的 分析热毒宁注射液和痰热清注射液治疗小儿急性上呼吸道感染的成本-效果优势及社会效益。方法 回顾性调查323例急性上呼吸道感染患儿，其中使用热毒宁注射液的115例，痰热清注射液的101例，利巴韦林注射液的107例，以利巴韦林组为对照组，考察热毒宁组和痰热清组的成本-效果优势及社会效益。结果 热毒宁组和痰热清组的总有效率和不良反应发生率差异均无统计学意义（P>0.0125），但均优于利巴韦林组（P<0.0125）；3组成本-效果比分别为1.64、1.77和0.13；相对利巴韦林组，热毒宁组和痰热清组的增量成本-效果比分别为9.75和11.96。每治愈1例次患儿，痰热清组较热毒宁组多花8.82元，平均疗程多1.4 d，每家庭每例患儿年均将多花52.92元，年均将多占8.4天次诊疗机会，全院年均将多耗264.6万元，年均将多占42万天次诊疗机会。结论 治疗小儿急性上呼吸道感染，热毒宁注射液较痰热清注射液更具成本-效果优势和社会效益。 |
| 关键词: 热毒宁注射液 痰热清注射液 利巴韦林注射液 急性上呼吸道感染 成本-效果比 社会效益 |
| DOI：10.3969/j.issn.1674-070X.2017.07.017 |
| 投稿时间：2016-03-06 |
| 基金项目:国家自然基金项目（81373701）；湖南中医药大学青年教师科研基金项目（99820001-199）。 |
|
| Social Benefit and Cost-Effectiveness Analysis of 2 Traditional Chinese MedicineInjections on Acute Upper Respiratory Tract Infection |
| DENG Jia,SONG Xiangqing |
| (Department of Pharmacy, Maternity and Children Health Hospital of Hunan Province, Changsha, Hunan 410008, China;Department of Pharmacy, Hunan Cancer Hospital, Changsha, Hunan 410013, China) |
| Abstract: |
| Objective To analyze the cost-effectiveness and social benefit of Reduning injection and Tanreqing injection on acute upper respiratory tract infection. Methods The 323 children with acute upper respiratory tract infection were investigated retrospectively. Among them 115 children were treated by Reduning injection, 101 children by Tanreqing injection and 107 children by ribavirin injection, the ribavirin group as the control group. The cost-effectiveness and social benefit of the Reduning group and Tanreqing group were investigated. Results There were no significant differences about the effective rates and incidence of drug adverse events of the Reduning group and Tanreqing group (P>0.012 5), but the two groups were better than the ribavirin group (P<0.012 5). The ratios of cost-effectiveness were 1.64, 1.77 and 0.13 of the three groups, respectively. Compared with the ribavirin group, the ratios of incremental cost-effectiveness of the Reduning group and Tanreqing group were 9.84 and 11.96, respectively. The Tanreqing group costs extra 7.56 yuan and 1.4 d than the Reduning group every cured child. One child of each family would cost more 45.36 yuan and occupy more 8.4 days' diagnosis and treatment opportunity, and the whole hospital would cost more 2.268 million yuan and occupy more 0.42 million days' diagnosis and treatment opportunity. Conclusion Compared with the Tanreqing injection, Reduning injection in treating acute upper respiratory tract infection shows more cost-effectiveness advantage and social benefit. |
| Key words: Reduning injection Tanreqing injection ribavirin injection acute upper respiratory tract infection cost-effectiveness ratios social benefit |
|
二维码（扫一下试试看！） |
|
